Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Developmental Cell|April 20, 2016
Linking Smokers' Susceptibility to Tuberculosis with Lysosomal Storage DisordersAnnemarie H Meijer, Johannes M Aerts
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|June 14, 2003
Biochemistry of glycosphingolipid storage disorders: implications for therapeutic interventionJohannes M Aerts, Carla Hollak, Rolf Boot, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|March 8, 2011
Ceramide in lipid emulsions used in parenteral nutrition: an innocent bystander?Johanna E Groener, Mireille J Serlie, Aldi Poppema, et al.
International Review of Cytology|September 21, 2006
The biology of the Gaucher cell: the cradle of human chitinasesAnton P Bussink, Marco van Eijk, G Herma Renkema, et al.
Molecular Genetics and Metabolism|November 11, 2018
Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cellsNayiri Kaissarian, Justin Kang, Liming Shu, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 8, 2009
Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosisRolf G Boot, Carla E M Hollak, Marri Verhoek, et al.
International Journal of Molecular Sciences|November 25, 2023
Animal Models for the Study of Gaucher DiseaseOr Cabasso, Aparna Kuppuramalingam, Lindsey Lelieveld, et al.
American Journal of Clinical Pathology|September 15, 2004
Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophagesLeonie A Boven, Marjan van Meurs, Rolf G Boot, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 30, 2020
Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry diseaseDaniel G Bichet, Johannes M Aerts, Christiane Auray-Blais, et al.
Orphanet Journal of Rare Diseases|March 25, 2016
Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patientsBouwien E Smid, Maria J Ferraz, Marri Verhoek, et al.
Pageof 6